Post by Simon-Kucher

MFN is forcing biotech leaders to rethink some of their most important commercialization decisions. Pricing, launch timing, market access, and partnership strategies are becoming more interconnected than ever before. The result is a new set of trade-offs that can directly influence global asset value. Our latest whitepaper explores how late-stage biotechs can prepare for this shift. skp.link/jh2l #BetterBiotechGrowth #Biotech #MarketAccess #PharmaPricing #MFN